Search clinical trials for: Cyclophosphamide as GVHD prophylaxis

Total 469639 results

Siriraj Hospital

Not yet recruiting

The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen (CMV)

CMV Infection or Reactivation After Allogenic HSCT
Instituto Nacional de Cancer, Brazil

Not yet recruiting

PTCy and ATG for MSD and MUD Transplants

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma
Nantes University Hospital

Not yet recruiting

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation (CY-MET-RIC)

Hematologic Malignancy | Graft Versus Host Disease
Federal Research Institute of Pediatric Hematology...

Recruiting

PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

Inborn Errors of Immunity

Russian Federation
Shanghai Jiao Tong University School of Medicine
Shanghai Clinical Research Center

Not yet recruiting

Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis

GVHD

China
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (OPTIMIZE)

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Acute Leukemia | Myeloproliferative Neoplasm | Pro-Lymphocytic Leukemia

United States
Medical College of Wisconsin

Recruiting

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

Graft-versus-host Disease

United States
St. Jude Children's Research Hospital

Recruiting

A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies

Hematologic Malignancy | Myeloid Malignancy

United States
National Research Center for Hematology, Russia

Not yet recruiting

Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis (CY25)

Hematologic Malignancy | Graft Versus Host Disease | Cyclophosphamide Adverse Reaction
DKMS gemeinnützige GmbH

Recruiting

GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG (GRAPPA)

AML | MDS | Peripheral Blood Stem Cell Transplantation | Graft Vs Host Disease | CMML | MDS/MPN

Germany
ExCellThera inc.
Memorial Sloan Kettering Cancer Center

Recruiting

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

Cord Blood Transplant | High Risk Myeloid Malignancies

United States
University of Sao Paulo General Hospital
Libbs Farmacêutica LTDA

Recruiting

GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide

Hematopoietic Neoplasm | Graft Vs Host Disease

Brazil
King Faisal Specialist Hospital & Research Center

Recruiting

Comparing Post-Transplant Cyclophosphamide as GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients (PTCy-PMAT)

Acute Myeloid Leukemia (AML) in Remission | Acute Lymphoblastic Leukemia (ALL) in Complete Remission

Saudi Arabia
Universitätsklinikum Hamburg-Eppendorf
Clinical Trial Center North (CTC North GmbH & Co. KG); DKMS Stiftung Leben...

Recruiting

Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Myelodysplastic Syndromes | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission

Germany, Spain, Italy, Austria, Czechia, Finland, Russian Federation
University of Liege
Belgian Hematological Society

Recruiting

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning (HLA)

Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Non Hodgkin Lymphoma | Myeloproliferative Disorder | Chronic Lymphoid Leukemia | Acute Myeloid Leukemia in Remission | Myeloproliferative Syndrome | Chronic Myeloid Leukemia in Remission | Acute Lymphoid Leukemia in Remission

Belgium
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

Paroxysmal Nocturnal Hemoglobinuria (PNH) | Severe Aplastic Anemia (SAA) | Hypo-Plastic Myelodysplastic Syndrome (MDS)

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Recurrent Small Lymphocytic Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm | Prolymphocytic Leukemia and other conditions

United States
National Cancer Institute (NCI)

Suspended

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV

HIV | Hematologic Malignancies

United States
Dimitrios Tzachanis, MD PhD
Bristol-Myers Squibb

Active, not recruiting

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

Hematologic Neoplasms | GVHD

United States
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) (1703/1801)

Lymphoma | Acute Leukemia | Myelodysplasia | Chronic Myelogenous Leukemia (CML)

United States
Fundación Pública Andaluza para la gestión de la...

Active, not recruiting

Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.

Multiple Myeloma | Hematopoietic Stem Cell Transplantation

Spain
University of Nebraska
National Cancer Institute (NCI)

Terminated

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
Spectrum Health Hospitals
Millennium Pharmaceuticals, Inc.

Completed

Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis

Hematological Malignancy

United States
Gruppo Italiano Trapianto di Midollo Osseo

Completed

Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies (GITMO-PHYLOS)

Myeloid Malignancies

Italy
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials...

Completed

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

Acute Leukemia | Myelodysplasia

United States
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)

Follicular Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma

United States
University of Alabama at Birmingham

Completed

Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis

Lymphoma | Leukemia | Myelofibrosis | Myelodysplastic Syndrome | Severe Aplastic Anemia | Allogeneic Transplant

United States
Nantes University Hospital

Terminated

Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC (CYRIC)

Graft Versus Host Disease

France
Stanford University

Completed

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Lymphoma, Non-Hodgkin | Hematologic Diseases | Leukemia | Acute GVHD

United States
Universitätsklinikum Hamburg-Eppendorf
Clinical Trial Center North (CTC North GmbH & Co. KG); Riemser

Active, not recruiting

Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma

Multiple Myeloma

Germany
Fred Hutchinson Cancer Center

Withdrawn

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

Recurrent Hodgkin Lymphoma | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Hematopoietic and Lymphoid System Neoplasm | Recurrent... and other conditions

United States
University of Cologne

Completed

Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT (OCTET-Ever)

Graft-versus-Host Disease

Germany
Assistance Publique - Hôpitaux de Paris

Completed

Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT (ATG-CyGVHD)

Graft vs Host Disease

France
Memorial Sloan Kettering Cancer Center

Terminated

GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant

Leukemia | Non-Hodgkin's Lymphoma | Myelodysplastic Syndrome

United States
St. Petersburg State Pavlov Medical University

Completed

PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis

Primary Myelofibrosis | Myeloproliferative Disorders

Russian Federation
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials...

Completed

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Acute Leukemia | Chronic Myelogenous Leukemia | Myelodysplasia | Small Lymphocytic Lymphoma

United States
Ivan S Moiseev

Completed

Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT

Immune System Diseases | Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Acute Lymphoid Leukemia

Russian Federation
National Cancer Institute (NCI)

Completed

Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

Renal Cell Carcinoma | Graft-Versus-Host Disease | Engraftment Syndrome

United States
Stanford University

Terminated

Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Hematologic Diseases | Leukemia | Hodgkin Lymphoma | Acute-graft-versus-host Disease | Non-Hodgkin Lymphoma (NHL)

United States
Hospital Israelita Albert Einstein

Terminated

Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis (CICLODECH)

Chronic Myelomonocytic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Acute Lymphoid Leukemia | Myeloproliferative Disease

Brazil
M.D. Anderson Cancer Center

Completed

Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide

Lymphoma | Hematologic Diseases | Leukemia | Myeloma

United States
The Affiliated Hospital of the Chinese Academy...

Completed

HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk

Acute Myeloid Leukemia

China
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
Tehran University of Medical Sciences

Unknown

Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis

Osteopetrosis

Iran, Islamic Republic of
Wang Xin

Not yet recruiting

Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT

GVHD

China
Peking University People's Hospital

Not yet recruiting

Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors

Myelodysplastic Syndromes | Acute Leukemia | Severe Aplastic Anemia
Beijing 302 Hospital

Not yet recruiting

Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade

Hematological Malignancies | Graft-versus-host Disease
M.D. Anderson Cancer Center
KSQ Therapeutics, Inc.

Recruiting

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Melanoma | Head and Neck Neoplasms | Lung Neoplasms | Advanced Solid Tumor

United States
Tanta University

Recruiting

Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

Breast Cancer Stage 2 and 3

Egypt
Peking University People's Hospital

Recruiting

ATG Plus Low-dose PT-Cy for GVHD Prevention

Hematologic Malignancy

China

Search clinical trials for: Cyclophosphamide as GVHD prophylaxis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations